Why the study?
Does combined therapy with eprosartan and moxonidine improve hemodynamic and cardiac parameters compared to monotherapy or vehicle in stroke-prone spontaneously hypertensive rats?
Does combined therapy with eprosartan and moxonidine improve hemodynamic and cardiac parameters compared to monotherapy or vehicle in stroke-prone spontaneously hypertensive rats?
In a rat model of advanced hypertension, combining sympathetic inhibition and angiotensin II blockade improved blood pressure and left ventricular pathology but did not provide additive benefits on cardiac function over ARB monotherapy.
No takes yet. Share an insight, caveat, or question.
Combined ARB and sympathetic inhibition adds no cardiac function benefit over ARB alone in hypertensive rats; leaves open remodeling gains and precludes clinical translation.
Mukaddam‐Daher et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: